Rockwell Medical, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2022. Financial statements are unaudited. Unless noted otherwise, dollar amounts below are in millions.
Business context
Rockwell Medical supplies hemodialysis concentrates and mixers and partners internationally to develop and commercialize TRIFERIC, its iron product. The company describes itself as the second-largest U.S. supplier of dialysis acid and bicarbonate concentrates. It discontinued U.S. commercialization of TRIFERIC and its U.S. applications, while continuing international partnerships. Management’s strategy is to grow the concentrates business and achieve profitability in 2024.
Key financial results and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Net sales | $18.7 | $16.0 | $53.5 | $46.6 |
| Gross profit (loss) | $0.8 | $(0.3) | $1.7 | $(0.2) |
| Gross margin | 4.2% | (2.1)% | 3.2% | (0.4)% |
| Operating loss | $(3.7) | $(7.0) | $(14.8) | $(22.0) |
| Net loss | $(4.2) | $(7.6) | $(16.3) | $(23.7) |
| Loss per share | $(0.40) | $(0.89) | $(1.75) | $(2.79) |
- Revenue rose 16.9% in Q3 and 14.8% for the nine-month period, primarily from revised DaVita pricing and higher prices to other customers. Management attributed improved gross profit to those changes.
- Q3 operating expenses declined year over year, notably research and product development and selling and marketing. Nine-month G&A increased modestly, including a one-time former-CEO severance charge.
- At September 30, cash and cash equivalents were $13.0, available-for-sale investments were $14.6, and working capital was $23.0. Operating cash use was $16.8 for the first nine months, versus $24.5 a year earlier. Cash ended the period at $13.0, down $0.3 from year-end 2021.
- Investing activities used $5.6 in the first nine months, principally reflecting purchases and sales of available-for-sale investments; financing activities provided $22.1, including equity proceeds and offsetting debt repayments.
- Term-loan carrying value was approximately $14.1 at September 30, net of unamortized costs and discount; scheduled principal was $15.0. The loan bears interest at a rate initially stated as 8.75% (effective rate 10.9%), matures in March 2025, and is secured by company assets. The company reported covenant compliance at quarter-end and as of the report date.
- Total liabilities were $38.1 and stockholders’ equity was $16.1 at September 30. Current assets were $42.4 and current liabilities were $19.3.
Material changes and developments
- DaVita’s April 2022 supply-contract amendment introduced price increases effective May 1, quarterly pass-through of certain inflationary costs (subject to caps), cost-control requirements, and a $10 minimum-cash covenant. A default could lead to termination of the supply agreement. DaVita also invested $15.0 in Series X convertible preferred stock.
- June registered and private placements generated approximately $14.9 net proceeds. The company issued common shares and warrants; the preferred stock is convertible, and the filings disclose substantial potential dilution from warrants and other securities.
- Effective May 13, 2022, the company completed a one-for-eleven reverse stock split; share and per-share figures were retroactively adjusted.
- On November 9, after quarter-end, Rockwell reacquired its hemodialysis-concentrate distribution rights from Baxter and terminated the exclusive distribution agreement. A nominal fee is payable in two equal installments in January and April 2023. The companies are transitioning customers, with remaining operational elements of the old agreement ending December 31, 2022.
- On November 10, the company amended its Innovatus loan: it was to prepay $5.0 of principal on November 14 and make interest-only payments until September 2023, when scheduled debt payments resume.
- On November 10, the company terminated its CFO without cause and appointed its CEO as interim principal financial officer.
Outlook, risks and unusual items
- Management expects improved margins for the remainder of 2022 and targets profitability in 2024. It believes available working capital and financing provide funds for operating requirements for at least twelve months from the filing date, but also says further capital may be needed and future financing may not be available on acceptable terms.
- The Baxter transition creates execution and profitability risks: Rockwell will assume direct sales and distribution responsibilities, may lose customers, and could incur losses under fixed-price transition arrangements if costs exceed pricing. Management expects the change to enable direct customer access, independent pricing and efficiency improvements; those benefits are not assured.
- Inflation, shortages of raw materials and equipment parts, diesel and trucking constraints, supply-chain disruption, labor conditions and adverse weather could raise costs or disrupt production and deliveries. DaVita cost-recovery provisions are capped, so some cost increases may not be passed through.
- The FPC home-infusion program is on hold after FDA requested additional support and preliminary study results suggested substantial further work and capital would be needed. Rockwell planned to seek FDA feedback on FPC for acute heart failure before determining a development path.
- COVID-19 and broader financial-market volatility may continue to affect operations and access to financing. The filing says routine legal proceedings are not expected to have a material effect; no material changes to previously disclosed risk factors were reported apart from the risks described above.
- The filing reports 17.5 million warrants, 1.36 million potential shares from preferred-stock conversion, and 20.3 million total potentially dilutive securities excluded from diluted loss per share as anti-dilutive at September 30. These figures make potential dilution an important consideration.
Most important facts for investors to verify
- Whether the company can execute the Baxter customer transition, retain customers and achieve positive unit economics under direct distribution.
- Actual cash use, liquidity relative to DaVita’s $10 minimum-cash covenant, and the impact of the $5.0 million post-quarter debt prepayment and revised repayment schedule.
- Whether pricing and capped inflation-cost pass-throughs are sufficient to sustain the reported gross-margin improvement.
- The current outstanding share count and potential dilution from pre-funded warrants, PIPE warrants, preferred conversion and other equity awards.
- Progress toward the 2024 profitability target, and whether additional capital will be required or available.
- The full terms and financial consequences of the Baxter termination and Innovatus loan amendments, and any material CFO-transition costs.